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A B S T R A C T
Background
Omega 6 plays a vital role in many physiological functions but there is controversy concerning its effect on cardiovascular disease
(CVD) risk. There is conflicting evidence whether increasing or decreasing omega 6 intake results in beneficial effects.
Objectives
The two primary objectives of this Cochrane review were to determine the effectiveness of:
1. Increasing omega 6 (Linoleic acid (LA), Gamma-linolenic acid (GLA), Dihomo-gamma-linolenic acid (DGLA), Arachidonic acid
(AA), or any combination) intake in place of saturated or monounsaturated fats or carbohydrates for the primary prevention of CVD.
2. Decreasing omega 6 (LA, GLA, DGLA, AA, or any combination) intake in place of carbohydrates or protein (or both) for the
primary prevention of CVD.
Search methods
We searched the following electronic databases up to 23 September 2014: the Cochrane Central Register of Controlled Trials (CEN-
TRAL) on the Cochrane Library (Issue 8 of 12, 2014); MEDLINE (Ovid) (1946 to September week 2, 2014); EMBASE Classic
and EMBASE (Ovid) (1947 to September 2014); Web of Science Core Collection (Thomson Reuters) (1990 to September 2014);
Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment Database, and Health Economics Evaluations
Database on the Cochrane Library (Issue 3 of 4, 2014). We searched trial registers and reference lists of reviews for further studies. We
applied no language restrictions.
Selection criteria
Randomised controlled trials (RCTs) of interventions stating an intention to increase or decrease omega 6 fatty acids, lasting at least six
months, and including healthy adults or adults at high risk of CVD. The comparison group was given no advice, no supplementation,
a placebo, a control diet, or continued with their usual diet. The outcomes of interest were CVD clinical events (all-cause mortality,
cardiovascular mortality, non-fatal end points) and CVD risk factors (changes in blood pressure, changes in blood lipids, occurrence
of type 2 diabetes). We excluded trials involving exercise or multifactorial interventions to avoid confounding.
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Data collection and analysis
Two review authors independently selected trials for inclusion, extracted the data, and assessed the risk of bias in the included trials.
Main results
We included four RCTs (five papers) that randomised 660 participants. No ongoing trials were identified. All included trials had at least
one domain with an unclear risk of bias. There were no RCTs of omega 6 intake reporting CVD clinical events. Three trials investigated
the effect of increased omega 6 intake on lipid levels (total cholesterol, low density lipoprotein (LDL-cholesterol), and high density
lipoprotein (HDL-cholesterol)), two trials reported triglycerides, and two trials reported blood pressure (diastolic and systolic blood
pressure). Two trials, one with two relevant intervention arms, investigated the effect of decreased omega 6 intake on blood pressure
parameters and lipid levels (total cholesterol, LDL-cholesterol, and HDL-cholesterol) and one trial reported triglycerides. Our analyses
found no statistically significant effects of either increased or decreased omega 6 intake on CVD risk factors.
Two studieswere supported by funding from theUKFoodStandards Agency andMedical ResearchCouncil.One studywas supported by
Lipid Nutrition, a commercial company in theNetherlands and theDutchMinistry of Economic Affairs. The final study was supported
by grants from the Finnish Food Research Foundation, Finnish Heart Research Foundation, Aarne and Aili Turnen Foundation, and
the Research Council for Health, Academy of Finland.
Authors’ conclusions
We found no studies examining the effects of either increased or decreased omega 6 on our primary outcome CVD clinical endpoints
and insufficient evidence to show an effect of increased or decreased omega 6 intake on CVD risk factors such as blood lipids and
blood pressure. Very few trials were identified with a relatively small number of participants randomised. There is a need for larger well
conducted RCTs assessing cardiovascular events as well as cardiovascular risk factors.
P L A I N L A N G U A G E S U M M A R Y
Omega 6 intake to prevent cardiovascular disease
Review question
We reviewed randomised controlled trials examining the effect of either increased or decreased omega 6 fatty acids for the primary
prevention of CVD in healthy adults or adults at high risk of CVD. Four RCTs met the inclusion criteria for this Cochrane review.
Background
Omega 6 is an essential fatty acid because humans cannot make it in their bodies and must obtain it in their diet. Omega 6 can be
obtained from a variety of dietary sources, such as vegetable oil and nuts. Omega 6 fatty acids play a vital role in many physiological
functions. They are particularly important for maintaining bone health, regulating metabolism, and in stimulating skin and hair growth.
Some evidence suggests that a proportionally higher intake of omega 6 fatty acids along with a low intake of saturated fat is associated
with significant reductions in coronary heart disease. In contrast, there is concern that high levels of omega 6 fatty acids may worsen
cardiovascular risk. There appears to be inconclusive evidence from observational studies and meta-analyses on the benefits of omega
6 intake on CVD outcomes.
Study characteristics
The evidence is current to 23 September 2014. In this Cochrane review, four trials met the inclusion criteria and we examined these
trials (660 participants) that assessed the effects of either increased or decreased omega 6 intake on lipid levels and blood pressure (major
risk factors for cardiovascular disease (CVD)). The diets were followed for 24 weeks. All four trials recruited both male and female
participants but varied in the type of participants recruited. Two trials recruited overweight or obese but otherwise healthy adults. One
trial recruited older men and post menopausal women, and the remaining trial recruited younger adults with hypercholesterolaemia.
Two trials were conducted in the UK, one in the Netherlands, and the remaining trial was conducted in Finland. Trials included a
relatively small number of participants and were at some risk of bias.
Two studieswere supported by funding from theUKFoodStandards Agency andMedical ResearchCouncil.One studywas supported by
Lipid Nutrition, a commercial company in theNetherlands and theDutchMinistry of Economic Affairs. The final study was supported
by grants from the Finnish Food Research Foundation, Finnish Heart Research Foundation, Aarne and Aili Turnen Foundation, and
the Research Council for Health, Academy of Finland.
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Key results
No differences in effects of increased or decreased omega 6 intake were seen on blood lipids and blood pressure, but this is based on
very few studies. No included trials reported CVD events. There is insufficient evidence to date from randomised controlled trials to
recommend increasing or reducing omega 6 for the prevention of CVD.
Quality of the evidence
There are very few included studies and therefore the results have to be interpreted with caution. Overall we regarded the trials were at
unclear risk of bias.
B A C K G R O U N D
Omega 6 is an essential fatty acid that plays a vital role in many
physiological functions but there is controversy concerning its ef-
fect on cardiovascular risk. Results from clinical trials and obser-
vational studies are inconsistent. There is a need to review the
current evidence from randomised controlled trials (RCTs) in this
area.
Description of the condition
Cardiovascular diseases (CVD) are a group of conditions that af-
fect the heart and blood vessels (WHO 2014), and include cere-
brovascular disease, coronary heart disease (CHD), and peripheral
arterial disease (PAD). One mechanism thought to cause CVD is
atherosclerosis, which is where a person’s arteries become blocked
by plaques or atheromas (NHS 2012). Atherosclerosis can cause
CVD when the arteries are completely blocked by a blood clot or
when a narrowed artery restricts blood flow limiting the amount
of blood and oxygen reaching organs or tissue (BHF 2013). Even
though arteries may narrow and become less elastic with age, the
processmay be accelerated by factors such as smoking, high choles-
terol, hypertension, obesity, a sedentary lifestyle, and ethnicity
(NHS 2012). Ruptures of unstable plaques may also cause CVD
by activating an inflammatory response in the body. This inflam-
matory response causes the structure of the atherosclerotic plaque
to weaken and rupture leading to the formation of blood clots
(Spagnoli 2007).
CVDs are the leading causes of death worldwide (WHO 2014),
and in 2008 an estimated 30% of all global deaths were due to
CVD (WHO 2014). The burden of CVD also varies substantially
between regions (Müller-Nordhorn 2008), for example, death
from ischaemic heart disease in France is one-quarter of that of the
UK (Law 1999). Furthermore, low- and middle-income countries
are disproportionally affected (WHO 2014): in 2001, three-quar-
ters of global deaths from CHD took place in low- and middle-
income countries (Gaziano 2010). Gaziano 2010 suggested that
this rapid increase in CHD burden is attributable to an increase in
life span, socioeconomic changes, and the acquisition of lifestyle-
related risk factors.
One key public health priority is targeting modifiable risk factors,
including dietary factors, for CVD prevention. Such risk factors
are extremely important since their modification has the potential
to lower CVD risk, making them a main target for interventions
aimed at CVD primary prevention. One major modifiable risk
factor is diet and dietary factors, such as a low consumption of
fruit and vegetables (Begg 2007), a high intake of saturated fat
(Siri-Tarino 2010), and a high consumption of salt (He 2010),
which have been found to be associated with CVD risk.
Description of the intervention
Omega 6 (or n-6) polyunsaturated fatty acids (PUFAs) are char-
acterised by the presence of at least two carbon-carbon double
bonds (Harris 2009), as are omega 3 fats. The distinction between
omega 6 and omega 3 is based on the position of this double bond
from the methyl group end of the fatty acid molecule (Hall 2009;
Calder 2013). For omega 6, the double bond pair is sixth from
the methyl terminus while for omega 3 the double bond is third
(Harris 2009; Calder 2013). Linoleic acid (LA) (18:2n-6), one of
the omega 6 fatty acids, is an essential fatty acid because the human
body is unable to synthesize it and must be obtained through the
diet (Groff 1995). Gamma-linolenic acid (GLA), another omega
6 fatty acid, may become conditionally essential in the event of
reduced activity of delta-6-desaturase, which is the enzyme that is
necessary for converting LA into GLA (Rincón-Cervera 2009).
Othermembers of the omega 6 group include GLA (18:3n-6), di-
homo-gamma-linolenic acid (DGLA) (20:3n-6), and arachidonic
acid (AA) (20:4n-6) which can be derived from LA and synthe-
sized in the healthy human body. LA is widely available in the
diet from a variety of sources, such as vegetable oils, nut oils, nuts,
poultry, meat, egg, milk, margarines, and spreads (Russo 2009).
As with omega 3, omega 6 fatty acids play a vital role in many
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physiological functions. They are particularly important for main-
taining bone health, regulating metabolism, and in stimulating
skin and hair growth. However, evidence on the effect of omega
6 on CVD risk remains controversial. A few studies suggest that
a proportionally higher intake of omega 6 fatty acids along with
a low intake of saturated fat is associated with significant reduc-
tions in CHD (Katan 2009). Indeed, findings from cohort studies
have shown omega 6 fatty acids to be inversely associated with
cardiovascular death and to be inversely associated with CHD risk
(Laaksonen 2005; Oh 2005). Furthermore, studies have shown
that omega 6 fatty acids reduce CVD risk factors such as low-
density lipoprotein cholesterol (LDL-cholesterol) (Hodson 2001;
Jakobsen 2009), and blood pressure (Hall 2009). In contrast,
there is concern that high levels of dietary of omega 6 will have a
pro-inflammatory effect by increasing the production of 2-series
prostaglandins and 4-series leukotrienes. Therefore, increased in-
takes of omega 6 may potentially worsen CVD risk (Russo 2009).
However, the American Heart Association recommend consum-
ing around 500 mg/day of omega 3 and 15 mg/day of LA (Harris
2010).
How the intervention might work
Dietary fat modification can improve CVD risk and risk factors. A
meta-analysis of observational studies suggests an inverse relation-
ship between omega 6 intake and CVD risk (Harris 2007). The
meta-analysis aimed to evaluate studies assessing the relationship
between blood/tissue omega 6 PUFA content and CHD events,
andwas based on 25 case-control studies with 1998 cases and 6913
controls. Harris 2007 found that LA content of blood and tissues
was inversely associated with CHD risk while AA was not related
to CHD risk. A recentmeta-analysis included only prospective co-
hort studies that provided multivariate-adjusted risk estimates for
dietary LA consumption on CHD endpoints (Farvid 2014). The
search identified 13 cohort studies that included 310,602 individ-
uals and 12,479CHDevents, including 5882CHDdeaths.Over-
all, Farvid 2014 reported a protective effect of LA intake against
CHD events and deaths. Replacing saturated fat intake with a 5%
energy increase from LA intake was found to be associated with
a 9% lower risk of CHD events and a 13% lower risk of CHD
deaths (Farvid 2014).
An earlier meta-analysis searched for trials between 1979 to 1999
examining the effect of individual fatty acids on blood lipids.The
results included 60 trials randomising 1672 participants and sug-
gested a beneficial effect of PUFAs (including omega 6) on blood
lipids (Mensink 2003). This is supported by a meta-analysis of
eightRCTs including13,614participantswhich found that replac-
ing saturated fatty acids by increasing PUFA consumption, includ-
ing omega 6, reduced the occurrence of CHD events (Mozaffarian
2010). ACochrane review of RCTs investigated the effect of reduc-
ing or modifying dietary fats on total CVDmortality and morbid-
ity over at least 6 months. The findings suggest that modification
of dietary fat by replacing saturated fats with monounsaturated
fatty acids or PUFAs reduces CVD risk (Hooper 2011).
However, there is concern that high levels of omega 6 fatty acids
compared with omega 3 fatty acids in the diet increases the pro-
duction of 2-series prostaglandins and 4-series leukotrienes com-
pared with 3-series prostaglandins and 5-series leukotrienes. As
the 2-series prostaglandins and 4-series leukotrienes exert a more
potent pro-inflammatory effect, omega 6 fatty acids may theoreti-
cally worsen cardiovascular risk (Russo 2009). This relationship is
disputed, but has led to the concept that the ratio between omega
6 and omega 3 fatty acids may be crucial, rather than absolute
intakes of either omega 6 or omega 3 fatty acids. In addition,
there is concern that highly unsaturated fatty acids such as AA
may increase the susceptibility of lipoproteins such as LDL and
very-low-density lipoproteins (VLDL) to oxidation, making them
more atherogenic (Russo 2009).
A number of studies have found no association between omega 6
intakes and risk of CVD. Earlier prospective cohort studies found
no association between dietary intakes of omega 6 fatty acids and
stroke (He 2003), CHD (McGee 1984; Pietinen 1997) and CHD
mortality (Esrey 1996). The Sydney Diet Heart Study, a RCT of
458men aged between 30 to 59 years with a recent coronary event,
reported increased rates of death from all causes, CHD, and CVD
when substituting dietary linoleic acid in place of saturated fats
(Ramsden 2013). A systematic review of 36 reviewed and peer-
reviewed studies reported no effect of LA dietary modification
intake on changes in AA levels in plasma, serum or erythrocytes
in adults (Whelan 2011). Chowdhury 2014, a recent systematic
review of prospective, observational studies and RCTs, reported
non-significant associations between omega-6 fatty acids supple-
mentation and coronary disease or outcomes.
Why it is important to do this review
There appears to be inconclusive evidence from observational
studies and meta-analyses on the benefit of omega 6 intake on
CVD outcomes. Therefore, an up-to-date systematic review is re-
quired to clarify the association between CVD risk and omega 6
intake. This can then provide guidance for national and interna-
tional agencies, practitioners, and members of the public.
A previous systematic review of RCTs has examined the effect of
change in dietary fat intake (including LA) on CVDmorbidity in
adults with or without CVD (Hooper 2011). Mozaffarian 2010,
another systematic review, examined increased total or omega 6
PUFAs in adults with or without CVD events. A recent systematic
review summarised the association between fatty acids (including
omega 6) and coronary disease. The RCTs of the review included
interventions that recorded coronary outcomes as an end point of
interest and were conducted predominantly in those with estab-
lished CVD (Chowdhury 2014). Therefore previous reviews have
not explicitly examined increased or decreased omega 6 intake
for the primary prevention of CVD (Mozaffarian 2010; Hooper
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2011; Chowdhury 2014). With this in mind, we undertook this
Cochrane review to assess the current evidence.We includedRCTs
that stated an intention to increase or decrease omega 6 fats by
following dietary advice, omega 6 supplementation, or a provided
diet. We examined the effects over longer time periods (at least six
months) as these are most relevant for public health interventions.
O B J E C T I V E S
The two primary objectives of this Cochrane review were to de-
termine the effectiveness of:
1. Increasing omega 6 (LA, GLA, DGLA, AA, or any
combination) intake in place of saturated or monounsaturated
fats or carbohydrates for the primary prevention of CVD.
2. Decreasing omega 6 (LA, GLA, DGLA, AA, or any
combination) intake in place of carbohydrates or protein (or
both) for the primary prevention of CVD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We includedRCTs.We included trials reported as full-text articles,
as abstracts only, and unpublished data.
Types of participants
Healthy adults (aged ≥ 18 years old) from the general world-
wide population and adults at moderate to high risk of CVD. As
this review focused on the primary prevention of CVD, we ex-
cluded people who had experienced a myocardial infarction (MI),
stroke, revascularization procedure (coronary artery bypass graft-
ing (CABG), or percutaneous transluminal coronary angioplasty
(PTCA)), people with angina, and people with angiographically
defined CHD. We also excluded people with type 2 diabetes, as,
while type 2 diabetes is a risk factor for CVD, interventions tar-
geting this condition are covered by the Cochrane Metabolic and
Endocrine Disorders Group.
Types of interventions
We included all RCTs of interventions that stated an intention
to increase or decrease omega 6 fatty acids. Interventions had to
involve dietary advice, supplementation, or provide a diet where
omega 6 fatty acids were either increased or decreased. Studies
could include any type of omega 6 or combination of omega 6
fatty acids. We considered trials involving an increase or decrease
in omega 6 fatty acids with energy replacement by carbohydrates,
omega 3, omega 9, saturated fats, protein, alcohol, or monoun-
saturated fats, and included studies with additional dietary inter-
ventions. We excluded trials with other major concomitant inter-
ventions, such as exercise or other multiple lifestyle interventions
to avoid confounding.
We also focused on follow-up periods of six months (24 weeks)
or longer. Follow-up was considered to be the time elapsed since
the start of the intervention and, therefore, we excluded any trials
with an intervention period of less than six months as longer term
studies examine sustained changes which are more relevant for
public health interventions. For the control group, we considered
trials where the comparison group was given no advice, no sup-
plementation, a placebo, a control diet, or continued with their
usual diet. This included dietary intakes that represent the typical
dietary composition for that setting.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Cardiovascular mortality.
3. Non-fatal end points such as MI, CABG, PTCA, angina,
angiographically defined CHD, stroke, carotid endarterectomy,
and PAD.
Secondary outcomes
1. Changes in blood pressure (systolic and diastolic blood
pressure) and blood lipids (total cholesterol, HCL cholesterol,
LDL cholesterol, triglycerides).
2. Occurrence of type 2 diabetes as a major CVD risk factor.
3. Adverse effects (as defined by the authors of the included
trials).
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL, the Cochrane Library) (Issue 8 of 12, 2014).
• MEDLINE (Ovid) (1946 to September week 2, 2014).
• EMBASE Classic + EMBASE (Ovid) (1947 to September
2014).
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• Web of Science Core Collection (Thomson Reuters) (1990
to September 2014).
• Database of Abstracts of Reviews of Effects (DARE),
Health Technology Assessment Database, and Health Economics
Evaluations Database on the Cochrane Library (Issue 3 of 4,
2014).
We adapted the preliminary search strategy forMEDLINE (Ovid)
for use in the other databases (Appendix 1). We also applied the
Cochrane sensitivity-maximising RCT filter (Lefebvre 2011) to
MEDLINE (Ovid) and adaptations of it to the other databases,
except CENTRAL.
We searched all databases from their inception to the dates indi-
cated, and imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.
We searched the clinical trial registers on the 18 January 2015
(Appendix 1). We also conducted a search of ClinicalTrials.gov (
www.clinicaltrials.gov), metaRegister of controlled trials (mRCT)
(www.controlled-trials.com/mrct), and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) Search Portal (apps.who.int/trialsearch/).
We contacted trial authors when necessary for any additional in-
formation.
Data collection and analysis
Selection of studies
Two review authors (LH, CC orNF) independently screened titles
and abstracts for inclusion and coded them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. If there were any
disagreements, we asked a third review author to arbitrate (KR).
We retrieved the full-text study reports/publication and two au-
thors (LH, CC) independently screened the full-text and identi-
fied studies for inclusion, and identified and recorded reasons for
exclusion of the ineligible studies. We resolved any disagreements
through discussion or, if required, we consulted a third review
author (KR). We identified and excluded duplicates and collated
multiple reports of the same study so that each study, rather than
each report, was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table.
Data extraction and management
We used a data collection form for trial characteristics and out-
come data that had been piloted on at least one trial included in
the review. Two review authors (LA, LH or CC) extracted the fol-
lowing study characteristics from included studies:
1. Methods: trial design, total duration of trial, details of any
’run-in’ period, number of trial centres and location, trial setting,
withdrawals, and date of trial.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, smoking history, inclusion
criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. For intervention and control (during intervention): the
percentage of energy from omega 3, omega 6, omega 9, saturated
fats, monounsaturated fats, carbohydrates (refined and unrefined
if possible), alcohol, protein, and omega 6/omega 3 ratio.
5. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
6. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (LA, LH or CC) independently extracted out-
come data from included trials. We resolved disagreements by
consensus or by involving a third review author (KR). One re-
view author (LH) transferred data into RevMan 2014.We double-
checked that data were entered correctly by comparing the data
presented in the systematic review with the data in the trial reports.
A second review author (LA) spot-checked trial characteristics for
accuracy against the trial reports.
Assessment of risk of bias in included studies
Two review authors (LA, LH or CC) independently assessed risk
of bias for each included trial using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We resolved any disagreements by discussion or by involv-
ing another review author (KR). We assessed the risk of bias ac-
cording to the following domains:
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias (e.g. industry funding).
We graded each potential source of bias as either ’high’, ’low’, or
’unclear’ and provided a quote from the study report together with
a justification for our judgement in the ’Risk of bias’ table. We
summarised the ’Risk of bias’ judgements across different studies
for each of the domains listed. Where information on risk of bias
related to unpublished data or correspondence with a trial author,
we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
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Assessment of bias in conducting the systematic
review
We conducted this Cochrane review according to its published
protocol, Hartley 2014, and reported any deviations from it in the
’Differences between protocol and review’ section.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) with 95% con-
fidence intervals (CIs) and continuous data as mean difference
(MD) or standardised mean difference (SMD) with 95% CIs. We
entered data presented as a scale with a consistent direction of ef-
fect, with the exception of HDL cholesterol where an increase in
this outcome is a positive finding.
We intended to narratively describe skewed data reported as me-
dians and interquartile ranges but this did not apply to any of the
included trials.
Unit of analysis issues
Studies with multiple intervention groups
Data for the control group have been used for each intervention
group comparison. We reduced the weight assigned to the control
group by dividing the control group N by the number of inter-
vention groups analysed.
Cluster-RCTs
We intended to analyse cluster-RCTs using the unit of randomi-
sation (cluster) as the number of observations, and use individ-
ual level means and SDs adjusted for clustering together with the
number of clusters in the denominator, where needed, in order
to weight the trials appropriately. However we did not find any
cluster-RCTs that met the inclusion criteria.
Cross-over studies
For included cross-over studies we only used the first period.
Dealing with missing data
We contacted trial authors or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible (e.g. when a study is identified as abstract only).
Where this was not possible, and the missing data were thought to
introduce serious bias, we explored the impact of including such
studies in the overall assessment of results using a sensitivity anal-
ysis. Where papers did not report results as change from baseline
we calculated this and for the SD differences followed the meth-
ods presented in the Cochrane Handbook for Systematic Reviews of
Interventions for imputing these (16.1.3.2 Imputing standard de-
viations for changes from baseline, Higgins 2011), and assumed
a correlation of 0.5 between baseline and follow-up measures as
suggested by Follman 1992.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (hetero-
geneity of greater than 50%), we reported it and explored possible
causes by pre-specified subgroup analysis.
Assessment of reporting biases
We were unable to pool more than 10 trials and so did not use a
funnel plot to explore possible small-study biases for the primary
outcomes.
Data synthesis
Weconducted statistical analysis usingRevMan 2014.Continuous
data were entered as the difference in means and SDs between
baseline and follow-up. In the absence of substantial heterogeneity
(greater than 50%) and if there was a sufficient number of trials,
we combined the results using a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Weplanned to carry out the following subgroup analyses but there
were an insufficient number of trials included to do this:
1. Omega 6 alone versus omega 6 plus other dietary
components.
2. Baseline risk.
3. Increase or decrease in omega 6.
4. Omega 6/omega 3 ratio.
5. Age.
6. Sex.
We also planned to assess the treatment effects of omega 6 accord-
ing to energy replacement (e.g. by what omega 6 is replacing or,
for a decrease in omega 6, what is replacing omega 6), including:
1. Carbohydrates.
2. Saturated fats.
3. Omega 3 fatty acids.
4. Omega 9 fatty acids.
5. Protein.
6. Alcohol.
7. Monounsaturated fats.
We intended to further explore the effects of the above different
energy replacements by using meta-regression on our primary out-
comes. However, none of the included trials reported our primary
outcomes and there was an insufficient number of included trials
reporting our secondary outcomes to conduct these analyses.
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We intended to use the formal test for subgroup interactions in
RevMan 2014.
Sensitivity analysis
Weplanned to carry out the following sensitivity analyses but there
were an insufficient number of trials included to do this:
1. Only including studies at low risk of bias (assessed using the
Cochrane ’Risk of bias’ assessment tool).
2. Only including studies where the alteration in omega 6
(and its energy replacement) is the only dietary intervention.
Reaching conclusions
We based our conclusions only on findings from the quantitative
or narrative synthesis of included studies for this Cochrane re-
view. We avoided making recommendations for practice and our
implications for research suggest priorities for future research and
outline what the remaining uncertainties are in the area.
R E S U L T S
Description of studies
Results of the search
The searches generated 6921 hits and 3999 after de-duplication.
After screening the titles and abstracts, we identified 152 papers
for formal inclusion and exclusion. Of these, four RCTs (five pa-
pers) met the inclusion criteria, and one of the four RCTs had two
relevant intervention arms (Moore 2006 High LA; Moore 2006
Low LA). We did not identify any ongoing trials. We have pre-
sented details of the flow of studies in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
The details of themethods, participants, intervention, comparison
group, and outcome measures for each of the included trials are
shown in the ’Characteristics of included studies’ table. Four trials,
including 664 participants, met the inclusion criteria.
All four trials recruited both male and female participants
(Sarkkinen 1998; Moore 2006 High LA; Moore 2006 Low LA;
OPTILIP 2006; Sluijs 2010). The trials varied in the participants
recruited. Two trials recruited overweight or obese but otherwise
healthy adults aged 35 to 65 years (Moore 2006 High LA; Moore
2006 Low LA), and 40 to 70 years (Sluijs 2010). One trial re-
cruited older men and post menopausal women aged 45 to 70
years (OPTILIP 2006). One trial recruited younger adults aged
23 to 58 years with hypercholesterolaemia (Sarkkinen 1998).
Two trials were conducted in the UK (Moore 2006 High LA;
Moore 2006 Low LA; OPTILIP 2006), one in the Netherlands
(Sluijs 2010), whilst the remaining trial was conducted in Finland
(Sarkkinen 1998).
All included trials had the same duration of follow-up (24 weeks)
(Sarkkinen 1998; Moore 2006 High LA; Moore 2006 Low LA;
OPTILIP 2006; Sluijs 2010).
Three trials reported on the effects of increasing omega 6 intake,
and two trials reported on decreasing omega 6 intake.
Three trials increased omega 6 intake and provided high LA oils
and spreads throughout the durationof the study (Sarkkinen 1998;
Moore 2006 High LA; Sluijs 2010) but the LA content varied
across studies.
The high LA intervention arm of the Moore 2006 trial, Moore
2006 High LA, increased the omega 6:omega 3 ratio by providing
sunflower fats (LA: α-linolenic acid (LNA) was 27:1 for sunflower
spreads and 63:0.1 for sunflower oil). This trial aimed to maintain
a low omega 3 intake hence participants were provided with white
fish but the portions were not reported. The control group of
Moore 2006 High LA received no intervention.
The third trial increased omega 6 intake by providing detailed
written instructions of food consumption, typically consumed in
a Finnish diet, tailored to participants own energy levels. In the
reduced-fat sunflower oil-enriched intervention diet, the goal was
to consume 30% of energy from fat (10% saturated fat, 10%
monosaturated fat, 10%polyunsaturated fat), 15%of energy from
protein, 55% of energy from carbohydrate, and 15 to 20 g of fibre
per day. Additionally, sunflower oil and margarine were provided
throughout the study. The content of LAwas not provided but the
mean consumption throughout the study was reported (13.3 ± 3.5
g/day). In the high fat, saturated fat-enriched control diet typical
of the normal Finnish diet, participants received detailed written
instructions on diet at their own energy level. However, the goal
was to consume 38% of energy from fat (18% saturated fat, 15%
monosaturated fat, 5% polyunsaturated fat), 15% of energy from
protein, 47% of energy from carbohydrate, and 15 to 20 g of fibre
per day. Butter and a small amount of low-erucic acid rapeseed oil
were provided (Sarkkinen 1998).
Another trial increased omega 6 by using cis-9,trans-11 conju-
gated linoleic acid (c9,t11 CLA).The c9,t11 CLA oil was manu-
factured from safflower oil and four capsules of 1 g oil each were
taken daily. Placebo capsules contained an equal amount of fat
and were composed of a blend of palm oil (80%) and soybean oil
(20%), which resembles the average fatty acid composition of the
fat consumed by a Western population (Sluijs 2010).
The low LA intervention arm of the Moore 2006 trial, Moore
2006 Low LA, decreased the omega 6:omega 3 ratio by providing
rapeseed fats (LA:LNA was 3:1 for rapeseed spread, and 2:1 for
rapeseed oil). The trial aimed to maintain a low omega 3 intake
hence participants were provided white fish but the portions were
not reported. The control group of Moore 2006 Low LA received
no intervention.
The second trial, OPTILIP 2006, decreased omega 6 intake by
providing oils and spreads for the duration of the study. The
spreads contained 4.7 g/100 g of LA and 0.8 g/100 g of ALA. The
LA and ALA contents of rapeseed (canola) oil were 19.7 g and
8.9 g/100 g respectively. Participants were also provided with two
small cans of tuna/week, the tuna was canned in high linoleic sun-
flower oil. The diet was designed to keep the intake of saturated
and monounsaturated fatty acids constant and to provide ~ 6% of
energy from PUFAs. The control had a higher omega 6 content
that was similar to the household food consumption as stated by
the authors. In the control diet, the LA and ALA contents of the
spreads were 39.6 g and 0.5 g/100 g. The LA and ALA contents of
high-oleic sunflower oil were 10.6 g and 0.3 g/100 g. Participants
in the control group were provided with two small cans of tuna/
week, and the tuna was canned in olive oil (OPTILIP 2006).
Four trials are awaiting assessment and we have presented details
in the ’Characteristics of studies awaiting classification’ section.
One trial with two relevant intervention arms needs to be trans-
lated from Norwegian (Natvig 1967 High LA; Natvig 1967 Low
LA). The English abstract is presented in the ’Characteristics of
studies awaiting classification’ table. This is a large trial but it was
conducted in the 1960s and there are insufficient details in the
abstract to determine the conduct of the trial (methods of ran-
domisation and allocation) and outcome data. The library were
unable to provide the full text record for one trial with a relevant
intervention arm (Nordoy 1981). We have presented the English
abstract in the ’Characteristics of studies awaiting classification’
table. This is a very small trial with only 10 participants and there
are insufficient details in the abstract to determine the conduct of
the trial (study design, follow-up time, and outcomes measured).
For the other two studies, no abstract was available and the library
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was unable to provide us with full text records (Singer 1991; Ryu
1999).
We did not identify any ongoing trials.
Excluded studies
We have presented details and reasons for exclusion of the
studies that most closely missed the inclusion criteria in the
’Characteristics of excluded studies’ table. The most common rea-
sons for exclusion of studies included the control group did not re-
ceive a minimal intervention or no intervention, studies included
alternative designs (not RCTs), and studies were short-term (< six
months follow-up) (see Figure 1).
Risk of bias in included studies
We have provided details regarding the risk of bias judgements for
the included trials in the ’Risk of bias’ tables in the ’Characteristics
of included studies’ section. Also, we have presented ’Risk of bias’
summaries in Figure 2 and Figure 3. We will include a ’Summary
of findings’ table and GRADE assessment in an update of this
Cochrane review.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
No details were provided for the method of random sequence
generation and allocation concealment in all included trials. We
judged this to be at unclear risk of bias for all included trials.
Blinding
One trial reported that blinding of participants was not carried
out and was judged to be at high risk of performance bias (Moore
2006 High LA; Moore 2006 Low LA). One trial reported that the
investigators were unaware of treatment allocations for the trial
duration and was judged to be at low risk of performance bias
(Sluijs 2010). One trial, Moore 2006 High LA; Moore 2006 Low
LA, clearly reported that outcome assessment personnel involved
in the study were blinded to the randomisation and was judged
at low risk of detection bias. One trial did not report details on
blinding (OPTILIP 2006) and was judged to be at unclear risk of
bias for both domains. One trial, Sarkkinen 1998, reported that
spreads were provided on a single-blind basis but no further details
were provided and this was judged as unclear risk of bias for both
performance and detection.
Incomplete outcome data
Two trials (Moore 2006 High LA; Moore 2006 Low LA; Sluijs
2010) were judged to be at low risk of bias as the number of drop-
outs was clearly presented for each study arm at each stage of the
trial. Two trials reported the number of drop-outs for the overall
sample but not per study arm and were judged to be at unclear risk
of bias (Sarkkinen 1998; OPTILIP 2006). None of the included
studies used an intention-to-treat (ITT) analysis.
Selective reporting
All trials presented outcomes as reported and were judged to be at
low risk of bias.
Other potential sources of bias
One trial,Moore 2006High LA;Moore 2006 LowLA, was judged
to be at low risk of bias as they clearly report power calculations,
comparability of baseline characteristics and there was no industry
funding. One trial was judged to be at unclear risk as it was not
underpowered, baseline characteristics were similar between the
two groups, but the study was partially funded by commercial
funds (Sluijs 2010). Two trials were judged to be at unclear risk
of bias because of insufficient information provided (Sarkkinen
1998; OPTILIP 2006).
Effects of interventions
Increased omega 6
Primary outcomes
None of the included trials reported data for our primary out-
comes (all-cause mortality, cardiovascular mortality, or non-fa-
tal end points such as MI, CABG, PTCA, angina, angiograph-
ically defined CHD, stroke, carotid endarterectomy, and PAD)
(Sarkkinen 1998; Moore 2006 High LA; OPTILIP 2006; Sluijs
2010).
Secondary outcomes
Blood pressure
Two trials of increased omega 6 intake reported data on systolic
(SBP) and diastolic (DBP) blood pressure. There was no signifi-
cant heterogeneity (I² statistic = 0%) for either SBP or DBP and
results are dominated by one larger trial (Sluijs 2010, 346 partic-
ipants randomised). The pooled analysis of two trials showed no
statistically significant effect of increased omega 6 intake on either
SBP (MD -0.79, 95% CI -3.0, 1.41; two trials, 387 participants;
Analysis 1.1) or DBP (MD -0.02, 95% CI -1.35 to 1.32; two
trials, 387 participants; Analysis 1.2).
Lipid levels
Three trials reported the effect of increased omega 6 intake on
lipid levels (Sarkkinen 1998; Moore 2006 High LA; Sluijs 2010).
For total cholesterol, therewas significant heterogeneity (I² statistic
= 51%) and results were dominated by one larger trial (Sluijs
2010). The pooled analysis of three trials showed no statistically
significant effect of increased omega 6 intake on total cholesterol
(MD 0.02, 95% CI -0.13 to 0.18; three trials, 460 participants;
Analysis 1.3).
For LDL-cholesterol, therewasmoderate heterogeneity (I² statistic
= 38%) and results were dominated by one larger trial (Sluijs
2010). The pooled analysis of the three trials showedno statistically
significant effect of increased omega 6 intake on LDL-cholesterol
(MD -0.01, 95% CI -0.14 to 0.12; three trials, 460 participants;
Analysis 1.4).
For HDL-cholesterol, there was no heterogeneity (I² statistic =
0%) and results were dominated by one larger trial (Sluijs 2010).
The pooled analysis of the three trials showed no statistically sig-
nificant effect of increased omega 6 intake on HDL-cholesterol
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(MD 0.01, 95% CI -0.04 to 0.06; three trials, 460 participants;
Analysis 1.5).
For triglycerides, there was no heterogeneity (I² statistic = 0%)
and results were dominated by one larger trial (Sluijs 2010). The
pooled analysis of the two trials showed no statistically significant
effect of increased omega 6 intake on triglycerides levels (MD0.03,
95% CI -0.07 to 0.12; two trials, 419 participants; Analysis 1.6).
Occurrence of type 2 diabetes as a major CVD risk factor
None of the included trials reported data on the occurrence of
type 2 diabetes.
Adverse effects
None of the included studies reported adverse effects.
Reduced omega 6
Primary outcomes
Two trials reported the effects of decreasing omega 6 and did not
report data for our primary outcomes (all-cause mortality, cardio-
vascular mortality, or non-fatal end points such as MI, CABG,
PTCA, angina, angiographically definedCHD, stroke, carotid en-
darterectomy, and PAD) (Moore 2006 Low LA; OPTILIP 2006).
Secondary outcomes
Blood pressure
One trial examined effects of decreasing omega 6 on SBP andDBP
(Moore 2006 Low LA). This single trial reported no statistically
significant effect of reduced omega 6 intake on either SBP (MD -
0.80, 95% CI -14.34 to 12.74; Analysis 2.1) or DBP (MD 0.60,
95% CI -6.82 to 8.02; Analysis 2.2).
Lipid levels
Two trials reported the effect of decreased omega 6 intake on lipid
levels (Moore 2006 Low LA; OPTILIP 2006). One of the trials,
OPTILIP 2006, included participants on lipid lowering drugs.
For total cholesterol, there was no heterogeneity (I² statistic = 0%)
and the pooled analysis of the two trials showed no statistically
significant effect of decreased omega 6 intake on total cholesterol
levels (MD 0.06, 95% -0.31 to 0.43; two trials, 114 participants;
Analysis 2.3).
For LDL-cholesterol, there was no heterogeneity (I² statistic = 0%)
and the pooled analysis of the two trials showed no statistically
significant effect of decreased omega 6 intake on LDL-cholesterol
levels (MD -0.04, 95% CI -0.36 to 0.29; two trials, 114 partici-
pants; Analysis 2.4).
For HDL-cholesterol, there was no heterogeneity (I² statistic =
0%) and the pooled analysis of the two trials showed no statis-
tically significant effect of decreased omega 6 intake on HDL-
cholesterol levels (MD -0.02, 95% CI -0.16 to 0.12; two trials,
114 participants; Analysis 2.5).
One trial reported the effect of reducing omega 6 on triglycerides
levels (OPTILIP 2006). The single trial reported no statistically
significant effect of reduced omega 6 intake on triglycerides (MD
0.13, 95% CI -0.11 to 0.37; Analysis 2.6).
Occurrence of type 2 diabetes as a major CVD risk factor
None of the included trials reported data on the occurrence of
type 2 diabetes.
Adverse effects
None of the included trials reported adverse effects.
D I S C U S S I O N
Summary of main results
This Cochrane review included four trials (five papers) that ran-
domised 660 participants. We did not identify any ongoing trials.
There were no RCTs on omega 6 intake reporting CVD clinical
events. Three trials investigated the effect of increased omega 6 in-
take on lipid levels (total cholesterol, LDL-cholesterol, and HDL-
cholesterol) (Moore 2006 High LA; Sarkkinen 1998; Sluijs 2010),
two trials reported triglycerides (Sarkkinen 1998; Sluijs 2010),
and two trials reported blood pressure (diastolic and systolic blood
pressure) (Moore 2006 High LA; Sluijs 2010). One trial, with two
relevant intervention arms, investigated the effect of increased and
decreased omega 6 intake on blood pressure parameters (Moore
2006 High LA; Moore 2006 Low LA). Two trials investigated the
effect of decreased omega 6 intake on lipid levels (total cholesterol,
LDL-cholesterol, and HDL-cholesterol) (Moore 2006 Low LA;
OPTILIP 2006) and one trial reported triglycerides (OPTILIP
2006). All included trials were at unclear risk of bias for most risk
of bias domains, but all four trials had a low risk of selective re-
porting bias.
Overall, our analyses found no statistically significant effects of
increased omega 6 intake on lipid levels in three trials measuring
these, or blood pressure in the two trials reporting this, but results
are restricted to very few relatively small trials and are therefore
limited. Two trials reported the effects of decreasing omega 6 on
blood lipids and found no effects of the intervention. Only one
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trial reported the effect of decreasing omega 6 on blood pressure
and found no effect of the intervention.
Overall completeness and applicability of
evidence
Very few studies met the inclusion criteria and results are there-
fore extremely limited. None of the included trials reported our
primary outcomes but trials were relatively small and short term.
No conclusions can be drawn as to the effects of increasing or
decreasing omega 6 on cardiovascular risk factors. Adverse events
were not reported in any of the included trials.
Although all included trials provided oils/spreads/capsules to
change omega 6 intake, the increased or decreased omega 6:
omega 3 ratio varied across studies. One study did not report the
LA amount but provided the mean values of LA consumption
(Sarkkinen 1998). This trial included foods typically consumed in
the Finnish diet but no further details were provided. Food items
rich in omega 6, such as poultry, meat, egg, milk, and nuts, were
not used to increase omega 6 intakes in any of the included trials
hence it is unclear how trial results translate to real life scenarios.
All trials included several study arms, some of which were irrele-
vant to this review, and therefore the number of randomised par-
ticipants for this review dropped substantially.
Quality of the evidence
Unclear risk of bias in most ’Risk of bias’ domains of the four
included trials makes overall interpretation of the data difficult.
Sample sizes were small and durations of follow-up did not exceed
24 weeks. None of the included trials used ITT analysis. We will
include a ’Summary of findings’ table and perform GRADE as-
sessments in an update of this Cochrane review.
Potential biases in the review process
We performed a comprehensive search across major databases for
interventions involving increased or decreased omega 6 intake for
this review. In addition, we checked reference lists of all primary
studies and review articles for additional references. Two review
authors independently performed all screening, inclusion and ex-
clusion determination, and data extraction.
Our strict inclusion criteria limited the number of studies available
for inclusion in this review. We only considered trials of follow-up
periods of six months (24 weeks) or more. Follow-up was consid-
ered to be the time elapsed since the start of the intervention and,
therefore, we excluded any trials with an intervention period of
less than six months. Whilst trials with longer term follow-up are
more relevant for public health interventions, this restriction has
substantially reduced the number of eligible studies for inclusion.
Agreements and disagreements with other
studies or reviews
A previous review of controlled trials found that replacement of
carbohydrates with PUFAs (which the authors considered may
be equal omega 6) was found to significantly reduce total choles-
terol levels (estimated regression coefficient for mean change, -
0.021mmol/L, 95% CI -0.027 to -0.015), HDL-cholesterol (es-
timated regression coefficient for mean change, -0.032 mmol/
L, 95% CI -0.042 to -0.022), LDL-cholesterol (estimated re-
gression coefficient for mean change, -0.019 mmol/L, 95% CI
-0.025 to -0.013) and triacylglycerol (estimated regression coef-
ficient for mean change, -0.026 mmol/L, 95% CI -0.031 to -
0.020) (Mensink 2003). Nonetheless, Mensink 2003 included
short term interventions and studies were not necessarily ran-
domised. A meta-analysis of cohort studies which explicitly exam-
ined the effect of LA intake onCHDoutcomes (myocardial infarc-
tion, ischemic heart disease, coronary artery bypass graft, sudden
cardiac arrest, acute coronary syndrome, and CHD deaths) found
a dose-response inverse association between dietary LA intake with
CHD risk (Farvid 2014). However, observational studies are open
to bias and confounding.
A recent meta-analysis of prospective, observational studies and
RCTs examined the association between fatty acids and coronary
disease. The meta-analysis of RCTs showed that omega-6 intake
did not significantly reduce the risk for coronary disease 0.86 (95%
CI 0.69 to 1.07). It should be noted that the RCTs were eligi-
ble for this review only if they recorded coronary outcomes as an
endpoint of interest (Chowdhury 2014) and were conducted pre-
dominantly in those with existing CVD, and so the focus of this
review was secondary rather than primary prevention unlike the
current review.
There have been previous systematic reviews of RCTs examining
the effects of PUFA, including omega 6 intake but not explicitly fo-
cusing on this, on cardiovascular risk factors including lipid levels
(Mozaffarian 2010; Hooper 2011) and CVD events (Mozaffarian
2010). These reviews used different inclusion criteria to the cur-
rent review. Participants were included with or without existing
CVD so the focus was not on primary prevention (Mozaffarian
2010; Hooper 2011). Additionally, it is difficult to disentangle the
effect of omega 6 as this was not explicitly examined in each of
the reviews (Mozaffarian 2010; Hooper 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We have avoided making implications for practice as there is cur-
rently insufficient evidence for the effects of increased or decreased
omega 6 intake on CVD events and CVD risk factors.
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Implications for research
Few trials met the inclusion criteria of this Cochrane review. All
included trials were small, relatively short term, and at some risk
of bias. None reported our primary outcomes. There is a need
for large, well-designed, long term RCTs to assess the effect of
increased or reduced omega 6 intake on cardiovascular events and
risk factors to determine the effectiveness of either intervention
for the primary prevention of CVD.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Moore 2006 High LA
Methods RCT with increased dietary omega 6:omega 3 ratio. Study was conducted in the UK
Participants 157 men and women between the age of 35 to 65 years and a BMI between 25 and 40
kg/m2 were recruited from the community.
Inclusion criteria:
• BMI between 25 and 40 kg/m².
• Between 35 and 65 years old.
• Not taking regular oil supplements.
• Not currently prescribed non-steroidal anti-inflammatory drugs, aspirin, steroids,
immunosuppressants, or lipid lowering drugs.
• No known diagnosis of diabetes, hypertension, hyperlipidaemia, asthma, or
chronic inflammatory disease.
• Not known or planned pregnancy.
Interventions Intervention:
• Low n-3 (high LA:LNA): (white fish/sunflower, N = 30, 33% males): white fish
and fat spreads and oils. LA:LNA was 27:1 for sunflower spread, and 63:0.1 for
sunflower oil.
• The fish was obtained from local supermarkets and volunteers selected items from
a range, including frozen fish, fishcakes, and tinned fish. The spreads and oils were
generously provided by Matthews Foods PLC. (Ossett, West Yorkshire, UK).
Control (N = 34, 34% males):
• No intervention
Follow-up: 24 weeks
Outcomes Blood pressure and lipid levels
Notes This was a 5-arm study: High n-3 (high LA:LNA), High n-3 (low LA:LNA), Low n-3
(high LA:LNA), Low n-3 (low LA:LNA), and control. We used just the Low n-3 (high
LA:LNA), and control arms only hence total number randomised was 64 participants
The control group N was divided in 2 in the meta-analyses to prevent double counting
Funding source: This study was supported by funding from the UK Food Standards
Agency and Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Minimization was used to assign subjects
to a control group or one of four parallel
intervention groups and to ensure that the
treatment armswere balanced for age, BMI,
gender, and habitual consumption of oily
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Moore 2006 High LA (Continued)
fish based on three categories (0, ≤ 1, or >
1 portion/week)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due to the nature of food-based interven-
tions, it was not possible for the principal
investigators or subjects to be blinded to
the randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory analysts, dietary coders, clinical
scientists, and statisticians involved in the
study were blinded to the randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of drop-outswas specified and rea-
sons provided.
Selective reporting (reporting bias) Low risk All outcomes stated were reported.
Other bias Low risk Not underpowered, baseline characteristics
are comparable, and the study was not in-
dustry funded
Moore 2006 Low LA
Methods RCT with decreased dietary omega 6:omega 3 ratio. Study was conducted in the UK
Participants 157 men and women between the age of 35 to 65 years and a BMI between 25 and 40
kg/m² were recruited from the community
Inclusion criteria:
• BMI between 25 and 40 kg/m².
• Between 35 and 65 years old.
• Not taking regular oil supplements.
• Not currently prescribed non-steroidal anti-inflammatory drugs, aspirin, steroids,
immunosuppressants, or lipid lowering drugs.
• No known diagnosis of diabetes, hypertension, hyperlipidaemia, asthma, or
chronic inflammatory disease.
• Not known or planned pregnancy.
Interventions Intervention:
• Low n-3 (low LA:LNA): (white fish/rapeseed, N = 29, 38% males): white fish and
fat spreads and oils. LA:LNA was 3:1 for rapeseed spread, and 2:1 for rapeseed oil.
• The fish was obtained from local supermarkets and volunteers selected items from
a range, including frozen fish, fishcakes, and tinned fish. The spreads and oils were
generously provided byMatthews Foods Plc. (Ossett, West Yorkshire, UK).
Control (N = 34, 34% males):
• No intervention.
Follow-up: 24 weeks
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Moore 2006 Low LA (Continued)
Outcomes Blood pressure and lipid levels
Notes This was a 5-arm study: High n-3 (high LA:LNA), High n-3 (low LA:LNA), Low n-3
(high LA:LNA), Low n-3 (low LA:LNA), and control. We used just the Low n-3 (low
LA:LNA), and control arms only and control arms only hence total number randomised
was 63 participants
The control group N was divided in 2 in the meta-analyses to prevent double counting
Funding source: This study was supported by funding from the UK Food Standards
Agency and Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As above (Moore 2006 High LA).
Allocation concealment (selection bias) Unclear risk As above (Moore 2006 High LA).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk As above (Moore 2006 High LA).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above (Moore 2006 High LA).
Incomplete outcome data (attrition bias)
All outcomes
Low risk As above (Moore 2006 High LA).
Selective reporting (reporting bias) Low risk As above (Moore 2006 High LA).
Other bias Low risk As above (Moore 2006 High LA).
OPTILIP 2006
Methods RCT with decreased omega 6 fats. Study was conducted in the UK
Participants OPTILIP study. 258men and postmenopausal women aged 45 to 70 years were recruited
from general practices participating in the UK Medical Research Council General Prac-
tice Research Framework. Staff of King’s College London and its associated hospitals
were also recruited for this study
Inclusion criteria:
• Both genders.
• Postmenopausal (aged 45 to 70) women. In the younger subjects, postmenopausal
status defined as a span of ≥ 1 year since menstruation and was confirmed by
measurement of the serum concentration of follicle-stimulating hormone.
• Subjects taking blood pressure or lipid-lowering medication were eligible if their
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OPTILIP 2006 (Continued)
medication regimens were stable.
Exclusion criteria:
• BMI < 20 or > 35 kg/m².
• Fasting serum cholesterol > 8 mmol/L or triacylglycerol > 6.0 mmol/L.
• Abnormal liver function or hematology.
• Clinical history of cholestatic liver disease, pancreatitis, diabetes mellitus, or
myocardial infarction.
• Current use of anticoagulants (excluding aspirin).
Interventions Intervention (N = 49, 63% males):
• Moderate linolenate diet where participants were provided with oils and spreads
for the duration of the study. The LA and ALA contents of the spreads were 4.7 and 0.
8 g/100 g. The LA and ALA contents of rapeseed (canola) oil were 19.7 g and 8.9 g/
100 g. Particpants were also provided with 2 small cans of tuna/week, the tuna was
canned in high linoleic sunflower oil.
• The diet was designed to keep the intake of saturated and monounsaturated fatty
acids constant and to provide ~ 6% of energy from PUFAs.
Control (N = 44, 68% males):
• Participants were provided with oils and spreads for the duration of the study. The
LA and ALA contents of the spreads were 39.6 g and 0.5 g/100 g. The LA and ALA
contents of high-oleic sunflower oil were 10.6 g and 0.3 g/100 g. Particpants were also
provided with 2 small cans of tuna/week, the tuna was canned in olive oil.
• The diet was designed to keep the intake of saturated and monounsaturated fatty
acids constant and to provide ~ 6% of energy from PUFAs.
Follow-up: 24 weeks
Outcomes Lipid levels
Notes The Quantification of the Optimal n6/n3 ratio in the UK Diet (OPTILIP) Study was
designed to assess the effects of lowering the dietary n6:n3 on CVD risk factors in older
people. The objective was achieved by using a food-based intervention that involved
increasing the relative intake of linolenic acid or n3 LC-PUFAs (notably EPA and DHA)
, or both, in relation to the intake of linoleic acid. This was a 5-arm study: n-3 LC-PUFA
+ linolenate, n-3 LC-PUFA, moderate linolenate diet, high linolenate, and control. We
used just the moderate linolenate (lower omega 6) and control arms (higher omega 6)
hence total number randomised was 93 participants
Funding source: Supported by the UK Food Standards Agency. Unilever Research, and
Mills DA, Norway, provided the spreads and the salmon spread, respectively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated. “Subjects were randomly as-
signed to 1 of 5 diets; subjects living to-
gether were allocated to the same treat-
29Omega 6 fatty acids for the primary prevention of cardiovascular disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OPTILIP 2006 (Continued)
ment”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details ofwithdrawals and lost to follow-up
were stated but not per study arm. Flow di-
agram was not provided. ITT analysis was
not used
Selective reporting (reporting bias) Low risk All outcomes stated were reported.
Other bias Unclear risk Insufficient information to judge. How-
ever, the study participants received a mod-
est financial reimbursement for their par-
ticipation in the study. They were provided
at regular intervals with some foods (yellow
fat spreads (i.e. butter, margarine, and low-
fat spreads), oil, and fish) for the dietary
intervention period
Sarkkinen 1998
Methods RCT with increased omega 6 fats. Study was conducted in Finland
Participants 160 men and women aged 23 to 58 years old with hypercholesterolemia were recruited
through the occupational health care system in the area of Kuopio in Eastern Finland
Inclusion criteria:
• Mild to moderate hypercholesterolaemia.
• Serum total cholesterol between 6.5 and 8.0 mmol/L before the study.
Exclusion criteria:
• Known diseases affecting serum lipid levels.
• Irregular eating patterns.
• Excess consumption of alcohol (> 45 g ethanol/d).
Interventions Intervention (N = 37, 43%males): Reduced-fat sunflower oil-enriched diet: participants
received detailed written instructions on diet at their own energy level. The goal was
to consume 30% of energy from fat (10% saturated fat, 10% monosaturated fat, 10%
polyunsaturated fat), 15%of energy fromprotein, 55%of energy from carbohydrate, and
15 to 20 g of fibre per day. The diet composed of normal food items, substituting low-fat
items for high-fat foods typically consumed in the Finnish diet; fatty acid composition
was adjusted by changing quality and quantity of fat spreads. Sunflower oil margarine
and sunflower oil were provided
Control (N = 36, 47% males): High fat, saturated fat-enriched control diet: participants
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Sarkkinen 1998 (Continued)
received detailed written instructions on diet at their own energy level. The goal was
to consume 38% of energy from fat (18% saturated fat, 15% monosaturated fat, 5%
polyunsaturated fat), 15%of energy fromprotein, 47%of energy from carbohydrate, and
15 to 20 g of fibre per day. The diet composed of normal food items, substituting low-fat
items for high-fat foods typically consumed in the Finnish diet; fatty acid composition
was adjusted by changingquality andquantity of fat spreads and subjects received detailed
written instructions on the diets at their own energy level. Butter and a small amount of
low-erucic acid rapeseed oil were provided
Follow-up: 24 weeks
Outcomes Lipid levels
Notes This is a 4-arm study: High fat, saturated fat enriched (control), reduced-fat sunflower
oil-enriched, reduced-fat rapeseed oil-enriched, and reduced-fat arm. We used just the
control and reduced-fat sunflower oil-enriched arms only hence total number randomised
was 73 participants
Funding source: Supported by grants from the Finnish Food Research Foundation,
Finnish Heart Research Foundation, Aarne and Aili Turunen Foundation, and the Re-
search Council for Health, Academy of Finland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Spreads provided on a single-blind basis but
no other details provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details ofwithdrawals and lost to follow-up
were stated but not per study arm. Flow di-
agram was not provided. ITT analysis was
not used
Selective reporting (reporting bias) Low risk All outcomes stated were reported.
Other bias Unclear risk Insufficient information to judge. Power
calculation was not carried out. Non-in-
dustrial funding
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Sluijs 2010
Methods RCT with increased omega 6 supplementation (cis-9,trans-11 conjugated linoleic acid)
. Study was conducted in the Netherlands
Participants 401 men and women between the age of 40 to 70 years old and BMI ≥ 25 kg/m² were
recruited through the Julius Center “POKA” database municipal registers of a large and
middle-large town in the middle part of the Netherlands
Inclusion criteria:
• Apparently healthy men and women
• Aged 40 to 70 years
• BMI ≥ 25 kg/m²
Interventions Intervention: High omega 6 (4 g CLA/d, N = 201, 48% males): The c9,t11 CLA oil was
manufactured from safflower oil. Four capsules of 1 g oil each were taken daily. CLA
capsules provided 80% CLA isomers, of which 80% (2.5 g/d) was c9,t11 CLA and 20%
(0.6 g/d) was t10,c12 CLA. The percentage of energy provided by c9,t11 CLA and t10,
c12 CLA during the intervention was around 1% and around 0.3%, respectively (based
on a daily intake of 2000 to 2500 kcal)
Control (N = 200, 48.6%males): Placebo capsules contained an equal amount of fat and
were composed of a blend of palm oil (80%) and soybean oil (20%), which resembles
the average fatty acid composition of the fat consumed by a Western population
Follow-up: 24 weeks
Outcomes Blood pressure and lipid levels
Notes Funding source: Supported by a grant from the Dutch Ministry of Economic Affairs
and by a grant from Lipid Nutrition BV, Wormerveer, Netherlands. Lipid Nutrition is
a commercial company focused on developing and producing specialty fats and oils
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Potential par-
ticipants were recruited through a random
selection from the municipal registers of a
large and middle-large town in the middle
part of the Netherlands. Minimisation was
used to assign subjects to a control group
or intervention group in a 1:1 ratio. Ran-
domisation was stratified for sex
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded study capsules were supplied in in-
dividual, pre-prepared, numbered bottles.
The investigators were unaware of treat-
ment allocations for the study duration
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Sluijs 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of drop-outswas specified and rea-
sons provided.
Selective reporting (reporting bias) Unclear risk All outcomes stated were reported.
Other bias Unclear risk Not underpowered, baseline characteristics
were similar between the two groups. The
study was partially funded by commercial
funds
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahrén 2009 Control not minimal and short term trial (12 weeks).
Allman-Farinelli 1999 Control not minimal and short term trial (6 weeks).
Anderson 1957 Short term trial (less than 4 weeks).
Angela Liou 2009 Short term trial (8 weeks).
Bachmair 2012 Control not minimal, irrelevant outcomes and short term trial (3 months)
Becker 1983 Control not minimal and short term trial (4 weeks).
Belury 2009 Control not minimal, participants irrelevant and short term trial (16 weeks)
Bemelmans 2000 Control not minimal (comparison against omega 3 intakes).
Bemelmans 2004 Control not minimal (comparison against omega 3 intakes).
Benito 2001 Control not minimal and short term trial (93 days).
Bermejo 2012 Intervention irrelevant and short term trial (12 weeks).
Bjermo 2012 Short term trial (10 weeks).
Blair 1993 Irrelevant outcomes and short term trial (100 days).
Boberg 1986 Short term trial (8 weeks).
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(Continued)
Bonanome 1992 Control not minimal and short term (3 weeks).
Bouwens 2009 Control not minimal (comparison against omega 3 intakes or low omega 3 intakes but with a similar
omega 6 content)
Brady 2004 Short term trial (12 weeks).
Bramkamp 1974 Not a RCT.
Bronsgeest-Schoute 1979 Control not minimal and short term trial (6 weeks).
Brox 1981 Control not minimal and short term trial (6 weeks).
Burdge 2004 Intervention, control and outcomes irrelevant and short term trial (8 weeks)
Camargo 2013 Intervention and control irrelevant and short term trial (12 weeks)
Carvalho 2012 Short term trial (90 days).
Cater 1997 Control not minimal and short term trial (3 weeks).
Clandinin 1999 Short term trial (21 days).
Dayton 1962 Irrelevant intervention.
de Kok 2003 Irrelevant outcomes and short term trial (6 weeks).
Deferne 1992 Control not minimal and short term trial (9 weeks).
Dembinska-Kiec 2010 Not a RCT.
Dembinska-Kiec 2011 Not a RCT.
Elisha 2011 Not a RCT.
Failor 1988 Not a RCT and short term trial (3 weeks).
Finnegan 2003a Irrelevant outcomes and control not minimal.
Finnegan 2003b Irrelevant intervention.
Friday 1991 Not a RCT and short term trial (3 weeks).
Gaullier 2004 Irrelevant intervention.
Gaullier 2005 Not a RCT and control irrelevant.
Gaullier 2007 Irrelevant intervention.
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(Continued)
Ghafoorunissa 1995 Control not minimal and short term trial (8 weeks).
Ghafoorunissa 2002 Not a RCT.
Giacco 2007 Intervention and control irrelevant and short term trial (3 months)
Groen 1965 Short term trial (5 weeks).
Grundt 1995 Intervention and control irrelevant and short term trial (12 weeks)
Grønn 1991 Not a RCT and short term trial (8 weeks).
Haglund 1998 Control not minimal and short term trial (4 weeks).
Harris 2009 Not a RCT.
Hartwich 2009 Control not minimal and short term trial (12 weeks).
Hartwich 2010 Control not minimal and short term trial (8 hours).
Heine 1989 Irrelevant participants.
Higdon 2000 Short term intervention (5 weeks).
Higdon 2001 Short term intervention (5 weeks).
Ho 1999 Irrelevant outcomes, control not minimal and short term trial (12 weeks)
Hodson 2001 Control not minimal and short term trial (2.5 weeks).
Hui 1989 Intervention in rats.
Hwang 1997 Short term trial (12 weeks).
Intorre 2013 Short term trial (4 weeks).
Iwata 2007 Control not minimal and short term trial (12 weeks).
Khan 2003 Irrelevant outcomes.
Kiecolt-Glaser 2013 Irrelevant intervention and outcomes and short term trial (4 months)
Kim 2009 Irrelevant intervention and short term trial (12 weeks).
Kingsbury 1961 Control not minimal and short term trial (6 weeks).
Knapp 1989 Short term trial (3 months).
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(Continued)
Koyama 2009 Not a RCT and short term trial (8 weeks).
Lambert 2007 Short term trial (12 weeks).
Lands 1992 Not a RCT.
Lee 2012 Short term trial (4 weeks).
Legrand 2010 Control not minimal and short term trial (90 days).
MARGARIN 2002 Irrelevant intervention.
Margolin 1990 Control not minimal and short term intervention (8 weeks).
Margolin 1991 Control not minimal and short term intervention (8 weeks).
McDaniel 2010 Irrelevant outcomes and short term trial (4 weeks).
Mendis 2001 Irrelevant intervention.
Miles 2004 Control not minimal, irrelevant outcomes and short term trial (12 weeks)
Mills 1989 Short term trial (28 days).
Minihane 2005 Control not minimal and short term trial (6 weeks).
Misikangas 2001 Irrelevant outcomes and short term trial (6 weeks).
Mortensen 1983 Control not minimal and short term trial (4 weeks).
Møller 1992 Control not minimal and short term trial (1 day).
Naber 1992 Short term trial (12 weeks).
Naumann 2006 Sort term trial (13 weeks).
Nelson 1997a Short term trial (50 days).
Nelson 1997b Short term trial (65 days).
Nestel 1992 Control not minimal and short term intervention (4 weeks).
Nestel 1995 Control not minimal and short term trial (3 weeks).
Noakes 1996 Control not minimal and short term trial (11 weeks).
Oe 2008 Short term trial (3 months).
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(Continued)
Paschos 2007 Control not minimal and short term trial (12 weeks).
Pa kowska 2012 Short term trial (12 weeks).
Perez-Martinez 2010 Irrelevant intervention, control and outcomes and short term trial (12 weeks)
Perkins 1958 Short term trial (7 weeks).
Radack 1990 Control not minimal and short term trial (8 weeks).
Radack 1991 Control not minimal and short term trial (12 weeks).
Rajaram 2012 Intervention irrelevant, irrelevant outcomes and short term trial (8 weeks)
Rallidis 2003 Control not minimal and short term trial (3 months).
Rallidis 2004 Control not minimal and short term trial (12 weeks).
Ramprasath 2012 Short term trial (20 days).
Reaven 1991 Short term trial (5 weeks).
Risérus 2002a Irrelevant intervention and short term trial (12 weeks).
Risérus 2002b Irrelevant intervention and short term trial (12 weeks).
Risérus 2004 Irrelevant intervention and short term trial (12 weeks).
Robertson 2002 Control not minimal and short term trial (1 day).
Roche 2009 Intervention and control irrelevant.
Sanders 1983 Intervention irrelevant and short term trial (2 weeks).
Sanders 1997 Control not minimal and short term trial (21 days).
Singer 1991 Control not minimal and short term trial (3 months).
Sirtori 1992 Short term trial (6 weeks).
Smedman 2001 Short term trial (12 weeks).
Sofi 2010 Not a RCT and short term trial (10 weeks).
Sofi 2013 Intervention and control irrelevant and short term trial (10 weeks)
Solà 1997 Control not minimal and short term trial (8 weeks).
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Song 2005 Control not minimal and short term trial (12 weeks).
Steck 2007 Control not minimal and short term trial (12 weeks).
Sundram 1992 Short term trial (6 weeks).
Svaneborg 1994 Control not minimal and short term trial (1 day).
Tavakkoli 2010 Control not minimal and short term trial (12 weeks).
Taylor 2006 Short term trial (12 weeks).
Tholstrup 2008 Irrelevant intervention and short term trial (16 weeks).
Tierney 2011 Intervention and control irrelevant and short term trial (12 weeks)
Truswell 2000 Short term trial (3 to 5 weeks).
Tsai 1997 Irrelevant control and short term trial (6 weeks).
Tsofliou 2009 Intervention irrelevant and short term trial (12 weeks).
Tulk 2009 No relevant outcomes and short term trial (8 hours).
Valsta 1996 Control not minimal, intervention irrelevant and short term trial (6 weeks)
Venter 1988 Short term trial (12 weeks).
Vergroesen 1980 Not a RCT.
Vericel 1987 Control not minimal and short term trial (2 months).
Vermunt 2001 Short term trial (6 weeks).
Viikari 1986 Not a RCT and short term trial (3 months).
West 2010 Short term trial (18 weeks).
Wilkinson 2005 Control not minimal and short term trial (12 weeks).
Yam 2001 Participants irrelevant and short term trial (12 weeks).
Zhao 2004 Short term (6 weeks).
Zhao 2007 No relevant outcomes and short term trial (6 weeks).
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Characteristics of studies awaiting assessment [ordered by study ID]
Natvig 1967 High LA
Methods RCT with increased omega-6 fats
Participants 16,615 men aged 50 to 59 years working in industrial and other firms in different parts of Norway
Interventions Intervention:
• Sunflower oil: 10 mL/day with approximately 63% LA
Control:
• Not given oil
Duration of the study:
52 weeks
Outcomes Morbidity and mortality of coronary and other vascular diseases
Notes Requires translation from Norwegian to determine details of the conduct of the trial, assessment of risk of bias and
outcome data
This is a 4-arm trial: Linseed oil, sunflower oil, and two control arms
English abstract: In collaboration with industrial physicians in Norway, a controlled 12-month trial was conducted
to assess the prophylactic effect of linoleic acid against coronary atherosclerosis, as suggested by P.A. Owren and
co-workers on the basis of laboratory experiments. The subjects were 16,615 men aged 50 to 59 years, working in
industrial and other firms in different parts of Norway. For each man, a health form was completed after a medical
examination or personal interview by the industrial physicians. The men were divided into 2 random groups; 1 group
of 6,720 men were given 10 mL of linseed oil daily with 55% of linoleic acid; the other group of 6,692 men were
given 10 mL of sunflower oil daily with approximately 63% linoleic acid. Two control groups were not given oil.
After 12 months, follow-up health forms for the men were returned from the industrial physicians, and the morbidity
and mortality of coronary and other vascular diseases were analysed. There were no statistically significant differences
between the linseed oil, sunflower oil, and control groups with regard to total mortality and mortality from coronary
disease, the incidence of coronary infarction and atherosclerosis obliterans, apoplexy, and thrombophlebitis. Thus,
the trial did not demonstrate any prophylactic effect from a daily dose of linseed oil or sunflower oil. Blood analyses of
a 5% random sample of the men in the oil and control groups revealed no significant difference in serum cholesterol
levels. As the numbers are small, however, there is no discrepancy between this lack of difference in the groups and a
calculated reduction of up to 10 mg% in serum cholesterol. There was no difference in platelet adhesiveness between
the oil groups and control groups. The trial revealed a significantly higher rate of coronary infarction, angina pectoris
and atherosclerosis obliterans in cigarette smokers than in non-smokers, and in men with persistently elevated blood
sedimentation rates compared with men with normal values. The trial clearly demonstrated that it is possible to carry
out large-scale prospective epidemiologic studies in Norway in cooperation with the industrial physicians
Natvig 1967 Low LA
Methods RCT with decreased omega-6 fats
Participants As above
Interventions Intervention:
• Linseed oil: 10 mL/day with 55% of LA
Control:
• Not given oil
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Natvig 1967 Low LA (Continued)
Duration of the study: 52 weeks
Outcomes As above
Notes As above
Nordoy 1981
Methods Cross over design - increased omega 6 fats
Participants 10 healthy male participants
Interventions • 25 mL cod liver oil
• 25 mL corn oil
• Unclear if there was a control arm
Outcomes Not clear if secondary outcomes (lipid levels) were reported
Notes Library unable to find.
Abstract: Ten healthy male subjects on an ordinary diet were given daily dietary supplement of 25 mL cod liver oil
(CLO) or corn oil (CO) for periods of 6 weeks in a crossover study. Significant changes were observed in the plasma
total fatty acid composition. The main platelet phospholipids fractions were also significantly altered, particularly by
CLO with an increase of the eicosapentaenoic acid (EPA): arachidonic acid (AA) ratio. Both supplements reduced
collagen induced platelet aggregation and TXB2 production, with CLO as the most potent one. No spontaneous
release of an anti-aggregatory substance or 6-keto-PGF1 alpha from vein tissues were found, and the total urinary
excretion of prostaglandin metabolites (E and F series) remained unchanged
Ryu 1999
Methods No information.
Participants No information.
Interventions No information.
Outcomes No information.
Notes Library unable to find.
Singer 1993
Methods No information.
Participants No information.
Interventions No information.
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Singer 1993 (Continued)
Outcomes No information.
Notes Library unable to find.
41Omega 6 fatty acids for the primary prevention of cardiovascular disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Increased omega 6 versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure, change
from baseline
2 387 Mean Difference (IV, Fixed, 95% CI) -0.79 [-1.00, 1.41]
2 Diastolic blood pressure, change
from baseline
2 387 Mean Difference (IV, Fixed, 95% CI) -0.02 [-1.35, 1.32]
3 Total cholesterol, change from
baseline
3 460 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.13, 0.18]
4 LDL cholesterol, change from
baseline
3 460 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.14, 0.12]
5 HDL cholesterol, change from
baseline
3 460 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.04, 0.06]
6 Triglycerides, change from
baseline
2 419 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.07, 0.12]
Comparison 2. Reduced omega 6 versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure, change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Diastolic blood pressure, change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Total cholesterol, change from
baseline [mmol/L]
2 114 Std. Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.31, 0.43]
4 LDL cholesterol, change from
baseline
2 114 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.36, 0.29]
5 HDL cholesterol, change from
baseline
2 114 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.16, 0.12]
6 Triglycerides, change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Increased omega 6 versus control, Outcome 1 Systolic blood pressure, change
from baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 1 Systolic blood pressure, change from baseline
Study or subgroup Increased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 High LA 27 -4.8 (17.05) 14 -2.2 (22.01) 2.8 % -2.60 [ -15.80, 10.60 ]
Sluijs 2010 173 -1.04 (10) 173 -0.3 (11.2) 97.2 % -0.74 [ -2.98, 1.50 ]
Total (95% CI) 200 187 100.0 % -0.79 [ -3.00, 1.41 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours increased omega 6 Favours control
Analysis 1.2. Comparison 1 Increased omega 6 versus control, Outcome 2 Diastolic blood pressure, change
from baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 2 Diastolic blood pressure, change from baseline
Study or subgroup Increased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 High LA 27 -5.1 (10.79) 14 -3.5 (11.23) 3.5 % -1.60 [ -8.75, 5.55 ]
Sluijs 2010 173 -0.21 (6.6) 173 -0.25 (6.3) 96.5 % 0.04 [ -1.32, 1.40 ]
Total (95% CI) 200 187 100.0 % -0.02 [ -1.35, 1.32 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours increased omega 6 Favours control
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Analysis 1.3. Comparison 1 Increased omega 6 versus control, Outcome 3 Total cholesterol, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 3 Total cholesterol, change from baseline
Study or subgroup Increased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Sarkkinen 1998 37 -0.32 (1.03) 36 0.13 (1.1) 9.8 % -0.45 [ -0.94, 0.04 ]
Moore 2006 High LA 27 0.04 (1.06) 14 0.04 (0.98) 5.5 % 0.0 [ -0.65, 0.65 ]
Sluijs 2010 173 0.02 (0.79) 173 -0.06 (0.79) 84.7 % 0.08 [ -0.09, 0.25 ]
Total (95% CI) 237 223 100.0 % 0.02 [ -0.13, 0.18 ]
Heterogeneity: Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours increased omega 6 Favours control
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Analysis 1.4. Comparison 1 Increased omega 6 versus control, Outcome 4 LDL cholesterol, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 4 LDL cholesterol, change from baseline
Study or subgroup Increased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 High LA 27 0.09 (0.89) 14 0.06 (0.88) 5.1 % 0.03 [ -0.54, 0.60 ]
Sarkkinen 1998 37 -0.33 (0.87) 36 0.05 (0.99) 9.1 % -0.38 [ -0.81, 0.05 ]
Sluijs 2010 173 0 (0.66) 173 -0.03 (0.66) 85.8 % 0.03 [ -0.11, 0.17 ]
Total (95% CI) 237 223 100.0 % -0.01 [ -0.14, 0.12 ]
Heterogeneity: Chi2 = 3.21, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours increased omega 6 Favours control
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Analysis 1.5. Comparison 1 Increased omega 6 versus control, Outcome 5 HDL cholesterol, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 5 HDL cholesterol, change from baseline
Study or subgroup Favours control Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 High LA 27 -0.01 (0.36) 14 0.03 (0.43) 3.7 % -0.04 [ -0.30, 0.22 ]
Sarkkinen 1998 37 0.04 (0.27) 36 0.11 (0.39) 10.8 % -0.07 [ -0.22, 0.08 ]
Sluijs 2010 173 -0.02 (0.26) 173 -0.04 (0.26) 85.5 % 0.02 [ -0.03, 0.07 ]
Total (95% CI) 237 223 100.0 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: Chi2 = 1.29, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours increased omega 6
Analysis 1.6. Comparison 1 Increased omega 6 versus control, Outcome 6 Triglycerides, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 1 Increased omega 6 versus control
Outcome: 6 Triglycerides, change from baseline
Study or subgroup Increased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Sarkkinen 1998 37 -0.21 (0.94) 36 -0.05 (0.75) 6.1 % -0.16 [ -0.55, 0.23 ]
Sluijs 2010 173 0.08 (0.4) 173 0.04 (0.53) 93.9 % 0.04 [ -0.06, 0.14 ]
Total (95% CI) 210 209 100.0 % 0.03 [ -0.07, 0.12 ]
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours increased omega 6 Favours control
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Analysis 2.1. Comparison 2 Reduced omega 6 versus control, Outcome 1 Systolic blood pressure, change
from baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 1 Systolic blood pressure, change from baseline
Study or subgroup Decreased omega 6 Control
Mean
Difference
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 Low LA 22 -3 (17) 14 -2.2 (22) -0.80 [ -14.34, 12.74 ]
-20 -10 0 10 20
Favours reduced omega 6 Favours control
Analysis 2.2. Comparison 2 Reduced omega 6 versus control, Outcome 2 Diastolic blood pressure, change
from baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 2 Diastolic blood pressure, change from baseline
Study or subgroup Decreased omega 6 Control
Mean
Difference
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 Low LA 22 -2.9 (10.81) 14 -3.5 (11.23) 0.60 [ -6.82, 8.02 ]
-20 -10 0 10 20
Favours reduced omega 6 Favours control
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Analysis 2.3. Comparison 2 Reduced omega 6 versus control, Outcome 3 Total cholesterol, change from
baseline [mmol/L].
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 3 Total cholesterol, change from baseline [mmol/L]
Study or subgroup Decreased omega 6 Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 Low LA 22 -0.08 (0.82) 14 0.04 (0.98) 30.5 % -0.13 [ -0.80, 0.54 ]
OPTILIP 2006 40 -0.04 (0.92) 38 -0.17 (0.92) 69.5 % 0.14 [ -0.30, 0.58 ]
Total (95% CI) 62 52 100.0 % 0.06 [ -0.31, 0.43 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours reduced omega 6 Favours control
Analysis 2.4. Comparison 2 Reduced omega 6 versus control, Outcome 4 LDL cholesterol, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 4 LDL cholesterol, change from baseline
Study or subgroup Decreased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 Low LA 22 -0.12 (0.77) 14 0.06 (0.88) 34.3 % -0.18 [ -0.74, 0.38 ]
OPTILIP 2006 40 -0.13 (0.92) 38 -0.17 (0.91) 65.7 % 0.04 [ -0.37, 0.45 ]
Total (95% CI) 62 52 100.0 % -0.04 [ -0.36, 0.29 ]
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Reduced omega 6 versus control, Outcome 5 HDL cholesterol, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 5 HDL cholesterol, change from baseline
Study or subgroup Decreased omega 6 Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
Moore 2006 Low LA 22 -0.01 (0.34) 14 0.03 (0.43) 28.1 % -0.04 [ -0.31, 0.23 ]
OPTILIP 2006 40 0.09 (0.37) 38 0.1 (0.38) 71.9 % -0.01 [ -0.18, 0.16 ]
Total (95% CI) 62 52 100.0 % -0.02 [ -0.16, 0.12 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 2.6. Comparison 2 Reduced omega 6 versus control, Outcome 6 Triglycerides, change from
baseline.
Review: Omega 6 fatty acids for the primary prevention of cardiovascular disease
Comparison: 2 Reduced omega 6 versus control
Outcome: 6 Triglycerides, change from baseline
Study or subgroup Decreased omega 6 Control
Mean
Difference
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Fixed,95% CI IV,Fixed,95% CI
OPTILIP 2006 40 0.05 (0.54) 38 -0.08 (0.54) 0.13 [ -0.11, 0.37 ]
-4 -2 0 2 4
Favours reduced omega 6 Favours control
A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library
#1MeSH descriptor: [Fatty Acids, Omega-6] this term only
#2“omega 6”
#3(n-6 near/4 acid*)
#4(“n 6” near/4 acid*)
#5omega-6
#6“linoleic acid*”
#7(poly* near/4 unsat* near/4 fatty acid*)
#8PUFA
#9MeSH descriptor: [Dietary Fats, Unsaturated] this term only
#10MeSH descriptor: [Corn Oil] this term only
#11((corn or maize or mazola) near/4 oil*)
#12maydol
#13lipomul*
#14MeSH descriptor: [Cottonseed Oil] this term only
#15cottonseed*
#16“cotton seed*”
#17MeSH descriptor: [Soybean Oil] this term only
#18intralipid or nutrilipid
#19((soy bean or soybean) near/4 (oil* or fat* or sauce*))
#20(so?a near/4 oil*)
#21so?aoil*
50Omega 6 fatty acids for the primary prevention of cardiovascular disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#22(soy near/4 oil*)
#23soyacal or travamulsion
#24(sunflower near/4 oil*)
#25helianth*
#26MeSH descriptor: [Safflower Oil] this term only
#27(safflower near/4 oil*) .tw.
#28liposyn
#29(grapeseed near/4 oil*)
#30#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31MeSH descriptor: [Cardiovascular Diseases] explode all trees
#32cardio*
#33cardia*
#34heart*
#35coronary*
#36angina*
#37ventric*
#38myocard*
#39pericard*
#40isch?em*
#41emboli*
#42arrhythmi*
#43thrombo*
#44atrial next fibrillat*
#45tachycardi*
#46endocardi*
#47(sick next sinus)
#48MeSH descriptor: [Stroke] explode all trees
#49(stroke or stokes)
#50cerebrovasc*
#51cerebral next vascular
#52apoplexy
#53(brain near/2 accident*)
#54((brain* or cerebral or lacunar) near/2 infarct*)
#55MeSH descriptor: [Hypertension] explode all trees
#56hypertensi*
#57(peripheral next arter* next disease*)
#58((high or increased or elevated) near/2 blood pressure)
#59MeSH descriptor: [Hyperlipidemias] explode all trees
#60hyperlipid*
#61hyperlip?emia*
#62hypercholesterol*
#63hypercholester?emia*
#64hyperlipoprotein?emia*
#65hypertriglycerid?emia*
#66MeSH descriptor: [Arteriosclerosis] explode all trees
#67MeSH descriptor: [Cholesterol] explode all trees
#68cholesterol
#69“coronary risk factor*”
#70MeSH descriptor: [Blood Pressure] this term only
#71“blood pressure”
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#72#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or
#49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #
67 or #68 or #69 or #70 or #71
#73#30 and #72
MEDLINE
1. Fatty Acids, Omega-6/
2. omega 6.tw.
3. (n-6 adj4 acid*).tw.
4. (n 6 adj4 acid*).tw.
5. omega-6.tw.
6. linoleic acid*.tw.
7. (poly* adj4 unsat* adj4 fatty acid*).tw.
8. PUFA.tw.
9. Dietary Fats, Unsaturated/
10. corn oil/
11. ((corn or maize or mazola) adj4 oil*).tw.
12. maydol.tw.
13. lipomul*.tw.
14. cottonseed oil/
15. cottonseed*.tw.
16. cotton seed*.tw.
17. soybean oil/
18. intralipid.tw.
19. nutrilipid.tw.
20. ((soy bean or soybean) adj4 (oil* or fat* or sauce*)).tw.
21. (so?a adj4 oil*).tw.
22. so?aoil*.tw.
23. (soy adj4 oil*).tw.
24. soyacal.tw.
25. travamulsion.tw.
26. (sunflower adj4 oil*).tw.
27. helianth*.tw.
28. Safflower Oil/
29. (safflower adj4 oil*).tw.
30. liposyn.tw.
31. (grapeseed adj4 oil*).tw.
32. or/1-31
33. exp Cardiovascular Diseases/
34. cardio*.tw.
35. cardia*.tw.
36. heart*.tw.
37. coronary*.tw.
38. angina*.tw.
39. ventric*.tw.
40. myocard*.tw.
41. pericard*.tw.
42. isch?em*.tw.
43. emboli*.tw.
44. arrhythmi*.tw.
45. thrombo*.tw.
46. atrial fibrillat*.tw.
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47. tachycardi*.tw.
48. endocardi*.tw.
49. (sick adj sinus).tw.
50. exp Stroke/
51. (stroke or stokes).tw.
52. cerebrovasc*.tw.
53. cerebral vascular.tw.
54. apoplexy.tw.
55. (brain adj2 accident*).tw.
56. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
57. exp Hypertension/
58. hypertensi*.tw.
59. peripheral arter* disease*.tw.
60. ((high or increased or elevated) adj2 blood pressure).tw.
61. exp Hyperlipidemias/
62. hyperlipid*.tw.
63. hyperlip?emia*.tw.
64. hypercholesterol*.tw.
65. hypercholester?emia*.tw.
66. hyperlipoprotein?emia*.tw.
67. hypertriglycerid?emia*.tw.
68. exp Arteriosclerosis/
69. exp Cholesterol/
70. cholesterol.tw.
71. “coronary risk factor* ”.tw.
72. Blood Pressure/
73. blood pressure.tw.
74. or/33-73
75. 32 and 74
76. randomized controlled trial.pt.
77. controlled clinical trial.pt.
78. randomized.ab.
79. placebo.ab.
80. drug therapy.fs.
81. randomly.ab.
82. trial.ab.
83. groups.ab.
84. 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83
85. exp animals/ not humans.sh.
86. 84 not 85
87. 75 and 86
EMBASE
1. omega 6 fatty acid/
2. omega 6.tw.
3. (n-6 adj4 acid*).tw.
4. (n 6 adj4 acid*).tw.
5. omega-6.tw.
6. linoleic acid*.tw.
7. (poly* adj4 unsat* adj4 fatty acid*).tw.
8. PUFA.tw.
9. edible oil/
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10. corn oil/
11. ((corn or maize or mazola) adj4 oil*).tw.
12. maydol.tw.
13. lipomul*.tw.
14. cotton seed oil/
15. cottonseed*.tw.
16. cotton seed*.tw.
17. soybean oil/
18. intralipid.tw.
19. nutrilipid.tw.
20. ((soy bean or soybean) adj4 (oil* or fat* or sauce*)).tw.
21. (so?a adj4 oil*).tw.
22. so?aoil*.tw.
23. (soy adj4 oil*).tw.
24. soyacal.tw.
25. travamulsion.tw.
26. sunflower oil/
27. (sunflower adj4 oil*).tw.
28. helianth*.tw.
29. safflower oil/
30. (safflower adj4 oil*).tw.
31. liposyn.tw.
32. (grapeseed adj4 oil*).tw.
33. or/1-32
34. exp cardiovascular disease/
35. cardio*.tw.
36. cardia*.tw.
37. heart*.tw.
38. coronary*.tw.
39. angina*.tw.
40. ventric*.tw.
41. myocard*.tw.
42. pericard*.tw.
43. isch?em*.tw.
44. emboli*.tw.
45. arrhythmi*.tw.
46. thrombo*.tw.
47. atrial fibrillat*.tw.
48. tachycardi*.tw.
49. endocardi*.tw.
50. (sick adj sinus).tw.
51. exp cerebrovascular disease/
52. (stroke or stokes).tw.
53. cerebrovasc*.tw.
54. cerebral vascular.tw.
55. apoplexy.tw.
56. (brain adj2 accident*).tw.
57. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
58. exp hypertension/
59. hypertensi*.tw.
60. peripheral arter* disease*.tw.
61. ((high or increased or elevated) adj2 blood pressure).tw.
62. exp hyperlipidemia/
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63. hyperlipid*.tw.
64. hyperlip?emia*.tw.
65. hypercholesterol*.tw.
66. hypercholester?emia*.tw.
67. hyperlipoprotein?emia*.tw.
68. hypertriglycerid?emia*.tw.
69. exp Arteriosclerosis/
70. exp Cholesterol/
71. cholesterol.tw.
72. “coronary risk factor*”.tw.
73. Blood Pressure/
74. blood pressure.tw.
75. or/34-74
76. 33 and 75
77. random$.tw.
78. factorial$.tw.
79. crossover$.tw.
80. cross over$.tw.
81. cross-over$.tw.
82. placebo$.tw.
83. (doubl$ adj blind$).tw.
84. (singl$ adj blind$).tw.
85. assign$.tw.
86. allocat$.tw.
87. volunteer$.tw.
88. crossover procedure/
89. double blind procedure/
90. randomized controlled trial/
91. single blind procedure/
92. 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91
93. (animal/ or nonhuman/) not human/
94. 92 not 93
95. 76 and 94
96. limit 95 to embase
Web of Science
# 19 #18 AND #17
# 18 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 17 #16 AND #8
# 16 #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
# 15 TS=(hyperlipid* OR hyperlip?emia* OR hypercholesterol* OR hypercholester?emia* OR hyperlipoprotein?emia* OR hyper-
triglycerid?emia*)
# 14 TS=(“high blood pressure”)
# 13 TS=(hypertensi* OR “peripheral arter* disease*”)
# 12 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME accident*) OR (brain SAME infarct*))
# 11 TS=(“atrial fibrillat*” OR tachycardi* OR endocardi*)
# 10 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
# 9 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 7 TS=((grapeseed near/4 oil*))
# 6 TS=((safflower N4 oil*) or liposyn)
# 5 TS=((sunflower N4 oil*) or helianth*)
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# 4 TS=(((soy bean or soybean) N4 (oil* or fat* or sauce*)) or (so?a N4 oil*) or intralipid or nutrilipid or so?aoil* or (soy near/4 oil*)
or soyacal or travamulsion)
# 3 TS=(cottonseed* or “cotton seed*”)
# 2 TS=(((corn or maize or mazola) N4 oil*) or maydol or lipomul*)
# 1 TS=(“omega 6” or “omega-6” or (n-6 N4 acid*) or (“n 6” N4 acid*) or “linoleic acid*” or (poly* N4 unsat* N4 fatty acid*) or
PUFA)
Clinical trial registers
Omega 6 and Cardio*
Omega 6 and primary prevention OR risk AND Cardio*
Omega 6
C O N T R I B U T I O N S O F A U T H O R S
LHo, KR, and LH contributed to the protocol development. LH, CC, and NF screened titles and abstracts and assessed studies for
inclusion and exclusion. LA, LH, and CC extracted data and assessed methodological rigour. Analyses were conducted by LA and
checked by KR. LH wrote the first draft of the review, which was updated by LA and KR.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not search AMED, as initially planned in Hartley 2014, because of lack of resources.
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